Clinical trial
Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral…
NCT00122603 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Completed
Key facts
| NCT number | NCT00122603 |
|---|---|
| Title | Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127) |
| Official title | Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Bristol-Myers Squibb Industry GlaxoSmithKline Hoffmann-La Roche |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Fosamprenavir, Saquinavir |
| Enrollment | 61 |
| Start date | Dec 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Jul 22, 2005 |
| Last update posted | Dec 22, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: